Figure 1.

Percentages of different systemic treatments and evolution of combination therapies. (a) Percentage of patients treated with each of the different systemic treatments, by year of follow-up. (b) Evolution of combination therapies used in the EMECAR cohort. Circle diameters are proportional to the number of patients with the corresponding combination therapy, the smallest ones representing one patient (gold salts plus sulfasalazine in 2000) and the biggest circle representing 35 patients (methotrexate plus TNF antagonists in 2004).